摘要 : Chimeric antigen receptor (CAR)-modified T cells and bispecific T cell-engaging antibodies have demonstrated dramatic clinical responses in recent clinical trials. The hallmark of these novel highly active immunotherapies is nonph... 展开
作者 | Maude~S.L. Barrett~D. Teachey~D.T. Grupp~S.A. |
---|---|
作者单位 | |
期刊名称 | 《The cancer journal》 |
总页数 | 4 |
语种/中图分类号 | 英语 / R73 |
关键词 | Acute lymphoblastic leukemia blinatumomab chimeric antigen receptor cytokine release syndrome |
馆藏号 | N2008EPST0005869 |